Swiss National Bank Has $12.24 Million Stake in Doximity, Inc. $DOCS

Key Points

• The Swiss National Bank reduced its stake in Doximity by 4.8%, selling 10,600 shares for a remaining ownership of 211,000 shares valued at approximately $12.24 million.
• Wall Street analysts have mixed views on Doximity's stock, with target prices ranging from $50.00 to $75.00, and a consensus rating of “Moderate Buy”.
• Doximity's recent quarterly earnings showed a 15.2% increase in revenue year-over-year, with an earnings per share (EPS) of $0.36, surpassing analyst expectations.

Swiss National Bank reduced its holdings in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 4.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 211,000 shares of the company's stock after selling 10,600 shares during the quarter. Swiss National Bank owned approximately 0.11% of Doximity worth $12,244,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. VSM Wealth Advisory LLC bought a new position in shares of Doximity during the 1st quarter worth approximately $29,000. Allworth Financial LP boosted its holdings in shares of Doximity by 104.0% in the 1st quarter. Allworth Financial LP now owns 563 shares of the company's stock valued at $32,000 after buying an additional 287 shares during the last quarter. Spire Wealth Management boosted its holdings in shares of Doximity by 73.2% in the 1st quarter. Spire Wealth Management now owns 615 shares of the company's stock valued at $36,000 after buying an additional 260 shares during the last quarter. Kapitalo Investimentos Ltda acquired a new stake in shares of Doximity in the 4th quarter valued at approximately $50,000. Finally, Cullen Frost Bankers Inc. acquired a new stake in shares of Doximity in the 1st quarter valued at approximately $64,000. 87.19% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on DOCS. Truist Financial increased their price objective on Doximity from $52.00 to $61.00 and gave the company a "hold" rating in a report on Thursday, July 17th. William Blair reaffirmed an "outperform" rating on shares of Doximity in a report on Friday, May 16th. JPMorgan Chase & Co. cut their price target on Doximity from $63.00 to $60.00 and set a "neutral" rating for the company in a report on Tuesday, May 27th. Morgan Stanley cut their price target on Doximity from $71.00 to $60.00 and set an "equal weight" rating for the company in a report on Thursday, April 24th. Finally, Raymond James Financial raised their price target on Doximity from $65.00 to $75.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, Doximity has a consensus rating of "Moderate Buy" and an average target price of $66.21.

Insider Activity at Doximity

In related news, Director Timothy S. Cabral sold 10,000 shares of the business's stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $60.00, for a total value of $600,000.00. Following the completion of the transaction, the director owned 6,360 shares of the company's stock, valued at $381,600. The trade was a 61.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kira Scherer Wampler sold 2,000 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $57.09, for a total value of $114,180.00. Following the completion of the transaction, the director directly owned 16,618 shares of the company's stock, valued at approximately $948,721.62. This trade represents a 10.74% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 36,000 shares of company stock valued at $2,140,940 over the last quarter. 31.30% of the stock is owned by corporate insiders.

Doximity Stock Down 3.3%

Shares of DOCS traded down $2.1850 during midday trading on Tuesday, reaching $63.7450. 183,670 shares of the stock were exchanged, compared to its average volume of 2,332,047. Doximity, Inc. has a twelve month low of $35.32 and a twelve month high of $85.21. The company has a market cap of $11.94 billion, a P/E ratio of 63.81, a PEG ratio of 4.10 and a beta of 1.36. The stock's 50 day simple moving average is $60.18 and its 200 day simple moving average is $60.32.

Doximity (NASDAQ:DOCS - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.36 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.05. Doximity had a return on equity of 21.75% and a net margin of 36.60%.During the same quarter in the prior year, the company earned $0.28 earnings per share. The firm's revenue was up 15.2% compared to the same quarter last year. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. As a group, analysts predict that Doximity, Inc. will post 0.99 earnings per share for the current year.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.